Sienna biopharmaceuticals, inc. (SNNA)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16Jun'16
Operating expenses:
Research and development

3,820

5,084

7,093

10,774

12,146

15,692

12,980

9,465

9,398

6,704

4,917

2,746

2,484

General and administrative

5,021

2,643

8,746

8,295

5,138

5,976

5,497

4,525

4,924

4,562

4,076

1,581

2,549

(Gain) loss on remeasurement of contingent consideration

-33,500

-

-

-

-700

-

-

-

-

-

-

-

-

Impairment of goodwill and in-process research and development

30,695

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

6,036

7,727

15,839

19,769

16,584

21,668

18,477

13,990

14,322

11,266

8,993

4,327

5,033

Loss from operations

-6,036

-7,727

-15,839

-19,769

-16,584

-21,668

-18,477

-13,990

-14,322

-11,266

-8,993

-4,327

-5,033

Reorganization items

2,003

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-549

-537

-543

434

-210

1,429

1,374

2,722

-2,154

-1,672

-1,160

217

106

Net loss before income taxes

-8,588

-

-

-

-16,794

-

-

-

-

-

-

-

-

Net loss before taxes

-

-

-

-

-

-

-

-11,268

-16,476

-12,938

-10,153

-4,110

-4,927

Income tax benefit

-4,618

-

-

-

-

-

-

-78

-85

-81

-46

-

-

Net loss

-3,970

-8,264

-16,382

-19,335

-16,794

-20,239

-17,103

-11,190

-16,391

-12,857

-10,107

-4,110

-4,927

Other comprehensive income (loss):
Cumulative translation adjustment

-1,469

586

-1,013

-655

-396

-2,494

1,374

671

1,588

2,706

771

-

-

Comprehensive loss

-5,439

-7,678

-17,395

-19,990

-17,190

-22,733

-15,729

-10,519

-14,803

-10,151

-9,336

-4,110

-4,927

Per share information:
Net loss, basic and diluted

-0.13

-0.27

-0.67

-0.92

-0.82

-1.00

-0.85

7.73

-1.12

-6.50

-5.30

-2.42

-2.91

Weighted average shares outstanding, basic and diluted

30,726

30,354

24,606

20,810

20,473

20,289

20,228

20,381

14,674

1,978

1,907

1,697

1,693